G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes. - Abstract - Europe PMC

G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

Schematic diagram illustrating mechanism by which GPR119 ligand

Frontiers Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

PDF) Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review

Targeting GPCRs Activated by Fatty Acid-Derived Lipids in Type 2 Diabetes: Trends in Molecular Medicine

PDF] G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment

GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment

GPR119 Agonists: A Novel Strategy for Type 2 Diabetes Treatment

Deciphering G-Protein-Coupled Receptor 119 Agonists as Promising Strategy against Type 2 Diabetes Using Systems Biology Approach